Sentence examples for recipient achieved from inspiring English sources

By 3 months, all but one CBT recipient achieved 98% donor chimerism; this patient had 92% donor chimerism at 90 days but relapsed and was excluded from further study.

Of interest, significantly more CZP recipients achieved remission at week 26 (29.5% vs 18.3%; P<0.05).

Before 1999, less than 10% of islet transplant recipients achieved insulin independence (1).

A retrospective study of all lung transplant recipients achieved during a 10-year period (from 1997 to 2006).

Two additional filgrastim recipients achieved complete remission after Induction 2, resulting in overall complete remission rates of 79% (33/42) in the pegfilgrastim group versus 68% (28/41) in the filgrastim group.

The combination of OLM/AML compared with PER/AML also enabled significantly more patients to control their BP; 76% of OLM/AML recipients achieved BP normalization based upon the ESH 2009 criteria [ 13].

The superiority of OLM/AML over PER/AML was also established for the majority of secondary efficacy variables; at the final examination, 75.6% of OLM/AML recipients achieved BP normalization (mean seated systolic BP/diastolic BP <140/90 mmHg) compared with 57.5% of PER/AML recipients (p < 0.0001).

Four weeks after vaccination, PsA-TT was able to elicit serum bactericidal antibody (SBA) titers 16-fold higher than the meningococcal ACWY quadrivalent polysaccharide vaccine (PsACWY) in 12- to 23-month-old children, and almost all vaccine recipients achieved SBA titers ≥128 [ 7], deemed to be a discriminatory titer [ 10, 11].

KM2760 combined with G-CSF treatment yielded an even more robust antitumour effect, with all recipients achieving complete remission, i.e. subcutaneous S-YU tumours completely vanished.

In addition, the hSBA assay against serogroup C appeared to distinguish further the MenACWY-TT vaccine from the licensed MenC-CRM197 vaccine, with 99.1% of MenACWY-TT recipients achieving post-vaccination hSBA titers ≥ 1 4 and ≥ 1 8, as compared with 72.1% of MenC-CRM197 vaccinees.

A total of 43% of insulin detemir recipients then achieved the <7% A1C target, compared with 17% continuing treatment with metformin + liraglutide.